Douglas J. Downs

Carolus Therapeutics, Inc. develops novel products for the treatment of inflammatory diseases. It company focuses on therapeutic strategies to noninvasively monitor and disrupt proinflammatory interactions of chemokines, and prevent or reverse inflammation associated with an array of human diseases, including atherosclerosis, rheumatoid arthritis, multiple sclerosis, sepsis, organ transplantation, and cancer. The company was founded by Jay Lichter, Jürgen Bernhagen, and Christian Weber in 2007 and is headquartered in San Diego, CA.

RQx Pharmaceuticals, Inc. operates as a biopharmaceutical company developing small molecule antibiotics. The firm develops small molecule antibiotics to combat serious life threatening infections, including those caused by multi drug-resistant Gram-negative bacteria. It is developing novel, first-in-class antibiotics that evade the current abundance of antibiotic resistance mechanisms, which are now common across the globe. The company was founded in 2010 and is headquartered in La Jolla, CA.

Carolus Therapeutics, Inc. develops novel products for the treatment of inflammatory diseases. It company focuses on therapeutic strategies to noninvasively monitor and disrupt proinflammatory interactions of chemokines, and prevent or reverse inflammation associated with an array of human diseases, including atherosclerosis, rheumatoid arthritis, multiple sclerosis, sepsis, organ transplantation, and cancer. The company was founded by Jay Lichter, Jürgen Bernhagen, and Christian Weber in 2007 and is headquartered in San Diego, CA.

Silarus Therapeutics, Inc. develops therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. The company was founded by Tomas Ganz, Sanford J. Madigan, and Elizabeta Nemeth in May 19, 2014 and is headquartered in La Jolla, CA.

Silarus Therapeutics, Inc. develops therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. The company was founded by Tomas Ganz, Sanford J. Madigan, and Elizabeta Nemeth in May 19, 2014 and is headquartered in La Jolla, CA.

RQx Pharmaceuticals, Inc. operates as a biopharmaceutical company developing small molecule antibiotics. The firm develops small molecule antibiotics to combat serious life threatening infections, including those caused by multi drug-resistant Gram-negative bacteria. It is developing novel, first-in-class antibiotics that evade the current abundance of antibiotic resistance mechanisms, which are now common across the globe. The company was founded in 2010 and is headquartered in La Jolla, CA.